Stress Urinary Incontinence (SUI) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Stress Urinary Incontinence (SUI) Market Outlook

Thelansis’s “Stress Urinary Incontinence (SUI) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Stress Urinary Incontinence treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Stress Urinary Incontinence (SUI) Overview

Stress urinary incontinence (SUI) is the sudden, involuntary loss of urine caused by heightened intraabdominal pressure, adversely affecting the patient's quality of life. Activities such as laughing, sneezing, straining, coughing, or exercising can trigger SUI, leading patients to describe the experience as "leaking," "dripping," or "flooding." Initial urinary complaints may include frequency, urgency, and dysuria.

The etiologies of stress urinary incontinence are diverse and include:

1. Loss of support from pelvic floor musculature and connective tissue stemming from factors such as connective tissue disorders, chronic cough, obesity, pelvic floor trauma post-vaginal delivery, pregnancy, menopause, constipation, heavy lifting, and smoking.
2. Neuromuscular damage resulting from prior pelvic surgeries.

In addition to SUI, three other types of incontinence merit consideration:

1. Overflow incontinence, characterized by continuous urinary leakage due to incomplete bladder emptying.
2. Urge incontinence, involving involuntary urine loss associated with a compelling, difficult-to-defer urge to void.
3. Mixed incontinence, marked by involuntary urine loss with elements of both urge and stress.

Managing stress urinary incontinence involves behavioral, pharmacological, and surgical approaches. Pharmacological options include:

1. Oxybutynin, an anti-cholinergic that inhibits detrusor contractions by blocking muscarinic receptors in the bladder's smooth muscle.
2. Tricyclic anti-depressants exert alpha-adrenergic effects, aiding urethral contraction and closure.
3. Topically applied estrogen to enhance urethral blood flow and the sensitivity of alpha-adrenergic receptors.

Stress UI tends to increase during pregnancy compared to pre-pregnancy, while urge UI remains relatively stable. In the initial three months postpartum, the prevalence of UI is 30%, with most women experiencing stress UI.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2022-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: